viral specific VST

Virus-specific VST (virus-specific T-cell therapy) is a form of adoptive cell therapy in which T cells that specifically recognize and target viral antigens are isolated or expanded ex vivo and then infused into immunocompromised patients to treat or prevent severe viral infections. The mechanism of action involves the direct recognition and elimination of virus-infected cells by the transferred virus-specific T lymphocytes. This approach is primarily used in patients who have undergone hematopoietic stem cell transplantation (HSCT) or solid organ transplantation, as these individuals are at high risk for life-threatening reactivation of latent viruses such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), adenovirus, BK virus, and JC virus. VSTs can be derived from the original stem cell donor or from partially HLA-matched third-party donors ("off-the-shelf" products). Manufacturing methods include direct isolation using multimer selection/IFNγ capture or ex vivo expansion with antigen-presenting cells loaded with relevant viral antigens. Clinical studies have shown high response rates and low toxicity profiles for this cellular immunotherapy[1][2][3][5].

Other names

virus-specific T-cell therapyvirus-specific T cellsVST therapy